Immunity to and Prevention of Herpes Zoster

1. Front Matter

   Pages I-VII

   PDF

2. The current status of live attenuated varicella vaccine

   • A. A. Gershon

   Pages 1-6

3. Evidence for frequent reactivation of the Oka varicella vaccine strain in healthy vaccinees

   • P. R. Krause

   Pages 7-15

4. Investigation of varicella-zoster virus variation by heteroduplex mobility assay

   • W. Barrett-Muir, K. Hawrami, J. Clarke, J. Breuer

   Pages 17-25

5. Varicella-zoster virus with a lost gE epitope: evidence for immunological pressure by the human antibody response

   • J. A. Padilla, C. Grose

   Pages 27-39

6. Biologic and geographic differences between vaccine and clinical varicella-zoster virus isolates

   • P. S. LaRussa, A. A. Gershon

   Pages 41-48

7. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses

   • Y. Gomi, T. Imagawa, M. Takahashi, K. Yamanishi

   Pages 49-56

8. Cis and trans elements regulating expression of the varicella zoster virus gI gene

   • H. He, D. Boucaud, J. Hay, W. T. Ruyechan

   Pages 57-70

9. Interactions among structural proteins of varicella zoster virus

   • M. Spengler, N. Niesen, C. Grose, W. T. Ruyechan, J. Hay

   Pages 71-79

10. The role of varicella zoster virus immediate-early proteins in latency and their potential use as components of vaccines

    • C. Sadzot-Delvaux, B. Rentier

    Pages 81-89

11. Mutagenesis of the varicella-zoster virus genome: lessons learned

    • J. I. Cohen

    Pages 91-97

12. Immune evasion mechanisms of varicella-zoster virus

    • A. Abendroth, A. Arvin

    Pages 99-107

13. Pathway of viral spread in herpes zoster: detection of the protein encoded by open reading frame 63 of varicella-zoster virus in biopsy specimens

    • T. Iwasaki, R. Muraki, T. Kasahara, Y. Sato, T. Sata, T. Kurata

    Pages 109-119

14. Vaccination against cytomegalovirus

    • S. A. Plotkin

    Pages 121-134

15. Varicella zoster virus in human and rat tissue specimens

    • P. W. Annunziato, O. Lungu, C. Panagiotidis

    Pages 135-142

16. In vitro measurement of human T cell responses to varicella zoster virus antigen

    • A. R. Hayward

    Pages 143-149

17. Use of varicella vaccines to prevent herpes zoster in older individuals

    • M. J. Levin

    Pages 151-160

18. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction

    • M. Takahashi, H. Kamiya, Y. Asano, K. Shiraki, K. Baba, T. Otsuka et al.

    Pages 161-172

19. Varicella-zoster virus immunity and prevention: a conference perspective

    • S. E. Straus

    Pages 173-178

20. Back Matter

    Pages 179-184

    PDF

Under sponsorship of the National Institutes of Health of Japan, an international conference entitled "Immunity and Prevention of Herpes Zoster" was held in 1 Osaka, Japan, March 8-10, 1999. Attendees included basic and clinical investi­ gators from Asia, Europe, and North America. The meeting was organized to explore progress made in basic virology and molecular understanding of varicella zoster (VZV), and to provide information on current knowledge of latency of VZV in humans. Updates on the immunology responses of humans to VZV, and a description of the current status of varicella vaccine worldwide were also included. In addition, the possibility of prevent­ ing zoster in people latently infected with wild-type VZV by immunizing them with varicella vaccine was presented. The papers in this volume include written summaries of most of the presentations given at that conference. Coincidentally but appropriately, the conference marked the twenty-fifth or "silver anniversary" of the first publication of the development and use of live varicella vaccine to prevent varicella, by Takahashi and his colleagues. Because varicella vaccine is the first herpesvirus vaccine licensed in use for humans, it is of special interest to all individuals who studied these pathogens. In view of the interest in developing vaccines against other herpes viruses, there was also a presentation on the current status of vaccines against cytomegaloviruses (CMV) at the conference.

• Gürtelrose
• Herpes zoster
• Impfung
• Infektion
• infection
• virus

• Department of Pediatrics, College of Physicians & Surgeons, Columbia University, USA

  Anne A. Gershon

• Department of Microbiology and Immunology, Stanford University, Stanford, USA

  Ann M. Arvin

• Arthropod-borne and Infectious Diseases Laboratory, Colorado State University, Fort Collins, USA

  Charles H. Calisher

Policies and ethics